Last reviewed · How we verify
Reducing dose of efavirenz
At a glance
| Generic name | Reducing dose of efavirenz |
|---|---|
| Sponsor | University Hospital, Geneva |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine (PHASE4)
- REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment (PHASE4)
- Metformin's Effect on Drug Metabolism in Patients With Type 2 Diabetes (PHASE1)
- Efavirenz 400mg in Treatment-naïve Chinese HIV-infected Patients (NA)
- Safety and Efficacy of Reduced Versus Standard Dose Efavirenz (EFV) Plus Two Nucleotides in Antiretroviral-naïve Adults. (PHASE3)
- Optimization of Antiretroviral Therapy (PHASE4)
- Therapeutic Drug Monitoring Study of Reduced-Dose Efavirenz (400 mg) in Combo Tablet for Patients Receiving Atripla With Viral Suppression in Taiwan (PHASE3)
- Pharmacokinetics and Pharmacodynamics of the Etonogestrel Contraceptive Implant When Co-administered With Efavirenz (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |